cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2020-35-1-133-141cardiotomsk-924Research ArticleЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯEXPERIMENTAL STUDIESСопряженность уровня гликемии и функциональных показателей миокарда у больных ишемической болезнью сердца на фоне сахарного диабета 2-го типаThe association of glycemia level and myocardial functional indices in patients with coronary heart disease and type 2 diabetes mellitushttps://orcid.org/0000-0002-4004-2497КондратьеваД. С.KondratievaD. S.

Cand. Sci. (Biol.), Research Scientist, Laboratory of Molecular and Cellular Pathology and Gene Diagnostics

111a, Kievskaya str., Tomsk, 634012, Russian Federation

dina@cardio-tomsk.ruhttps://orcid.org/0000-0001-6066-3998АфанасьевС. А.AfanasievS. A.

Dr. Sci. (Med.), Professor, Head of the Laboratory of Molecular and Cellular Pathology and Gene Diagnostics

111a, Kievskaya str., Tomsk, 634012, Russian Federation

tursky@cardio-tomsk.ruhttps://orcid.org/0000-0001-5004-1896БудниковаО. В.BudnikovaO. V.

Junior Research Scientist, Laboratory of Molecular and Cellular Pathology and Gene Diagnostics

111a, Kievskaya str., Tomsk, 634012, Russian Federation

budnikovaolesya@mail.ruhttps://orcid.org/0000-0002-4706-893XВорожцоваИ. Н.VorozhtsovaI. N.

Dr. Sci. (Med.), Professor, Leading Research Scientist, Department of Functional and Laboratory Diagnostics

111a, Kievskaya str., Tomsk, 634012, Russian Federation

vin@cardio-tomsk.ruhttps://orcid.org/0000-0002-0791-7466АхмедовШ. Д.AkhmedovSh. D.

Dr. Sci. (Med.), Professor, Deputy Director for Innovation and Strategic Development

111a, Kievskaya str., Tomsk, 634012, Russian Federation

shamil@cardio-tomsk.ruhttps://orcid.org/0000-0001-9887-8214ШипулинВ. М.ShipulinV. M.

Dr. Sci. (Med.), Professor, Principal Research Scientist

111a, Kievskaya str., Tomsk, 634012, Russian Federation

shvv@cardio-tomsk.ruHayчно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation202011042020351133141Copyright © Кондратьева Д.С., Афанасьев С.А., Будникова О.В., Ворожцова И.Н., Ахмедов Ш.Д., Шипулин В.М., 20202020Кондратьева Д.С., Афанасьев С.А., Будникова О.В., Ворожцова И.Н., Ахмедов Ш.Д., Шипулин В.М.Kondratieva D.S., Afanasiev S.A., Budnikova O.V., Vorozhtsova I.N., Akhmedov S.D., Shipulin V.M.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/924сахарный диабетишемическая болезнь сердцауровень гликемиигликированный гемоглобинструктурно-функциональные показатели сердцасократительная активность миокардаэкстрасистолические и постэкстрасистолические сокращенияpost-rest инотропная реакцияdiabetes mellitusischemic heart diseaseglycemic levelglycated hemoglobinstructural and functional parameters of the heartcontractile activity of the myocardiumextrasystolic and postextrasystolic contractionspost-rest inotropic reactionReferencesСахарный диабет 2-го типа: от теории к практике; под ред. И.И. Дедова, М.В. Шестаковой. М.: Медицинское информационное агентство; 2016:571.Type 2 diabetes mellitus: from theory to practice; еdit. by Dedov I.I., Shestakova M.V. Moscow: Moscow Inform Agency; 2016:571 (In Russ.).Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diabetes. 2015;6(13):1246–1258. DOI: 10.4239/wjd.v6.i13.1246.Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diabetes. 2015;6(13):1246–1258. DOI: 10.4239/wjd.v6.i13.1246.Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321(7258):405–412. DOI: 10.1136/bmj.321.7258.405.Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321(7258):405–412. DOI: 10.1136/bmj.321.7258.405.Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359(15):1577–1589. DOI: 10.1056/NEJMoa080647.Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359(15):1577–1589. DOI: 10.1056/NEJMoa080647.Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005;353(25):2643–2653. DOI: 10.1056/NEJMoa052187.Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005;353(25):2643–2653. DOI: 10.1056/NEJMoa052187.The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J Med. 2011;364(9):818–828. DOI: 10.1056/NEJMoa1006524.The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J Med. 2011;364(9):818–828. DOI: 10.1056/NEJMoa1006524.Skyler S., Bergenstal R., Bonow R., Buse J., Deedwania P., Gale E.A. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–357. DOI: 10.1161/CIRCULATIONAHA.108.191305.Skyler S., Bergenstal R., Bonow R., Buse J., Deedwania P., Gale E.A. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–357. DOI: 10.1161/CIRCULATIONAHA.108.191305.Zoungas S., Chalmers J., Neal B., Billot L., Li Q., Hirakawa Y. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014;371(15):1392–1406. DOI: 10.1056/NEJMoa1407963.Zoungas S., Chalmers J., Neal B., Billot L., Li Q., Hirakawa Y. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014;371(15):1392–1406. DOI: 10.1056/NEJMoa1407963.Bejan-Angoulvant T., Cornu C., Archambault P., Tudrej B., Audier P., Brabant Y. et al. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes? Diab. Metabol. 2015;41(3):195–201. DOI: 10.1016/j.diabet.2015.04.001.Bejan-Angoulvant T., Cornu C., Archambault P., Tudrej B., Audier P., Brabant Y. et al. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes? Diab. Metabol. 2015;41(3):195–201. DOI: 10.1016/j.diabet.2015.04.001.Wang P., Huang R., Lu S., Xia W., Sun H., Sun J. et al. HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc. Diabetol. 2015;14:124. DOI: 10.1186/s12933-015-0285-1.Wang P., Huang R., Lu S., Xia W., Sun H., Sun J. et al. HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc. Diabetol. 2015;14:124. DOI: 10.1186/s12933-015-0285-1.IDF Annual Report 2015 by İnternational Diabetes Federation. URL: issuu.com/int.diabetes. federation/docs/idf.IDF Annual Report 2015 by İnternational Diabetes Federation. URL: issuu.com/int.diabetes.federation/docs/idf.Рябова Т.Р., Рябов В.В., Соколов А.А., Дудко В.А., Репин А.Н., Марков В.А. и др. Динамика структурно-геометрических и функциональных показателей левого желудочка в ранние и поздние сроки инфаркта миокарда. Ультразвуковая и функциональная диагностика. 2001;(3):54–60.Ryabova T.R., Ryabov V.V., Sokolov A.A., Dudko V.A., Repin A.N., Markov V.A. et al. Left dynamics of structural geometrical and functional parameters on early and late terms of myocardial infarction. Ul’trazvukovaya i funkcional’naya diagnostika. 2001;(3):54–60 (In Russ.).Uhl S., Freichel M., Mathar I. Contractility measurements on isolated papillary muscles for the Investigation of Cardiac Inotropy in Mice. J. Vis. Exp. 2015;(103):53076. DOI: 10.3791/53076.Uhl S., Freichel M., Mathar I. Contractility measurements on isolated papillary muscles for the Investigation of Cardiac Inotropy in Mice. J. Vis. Exp. 2015;(103):53076. DOI: 10.3791/53076.Кондратьева Д.С., Афанасьев С.А., Реброва Т.Ю., Попов С.В. Сопряженность сократительной активности миокарда и уровня окислительного стресса у крыс при сочетанном развитии постинфарктного кардиосклероза и сахарного диабета. Известия Российской академии наук. Серия биологическая. 2019;(2):197–203.Kondratievа D.S., Afanasiev S.A., Rebrova T.Y., Popov S.V. Interrrelation between the сontractile activity of the myocardium and the level of oxidative stress in rats under concomitant development of postinfarction cardiosclerosis and diabetes mellitus. Biology Bulletin. 2019;(2):197–203 (In Russ.).Алгоритмы специализированной медицинской помощи больным сахарным диабетом; под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова; 8-й вып. М.: УП ПРИНТ; 2017:112.Standards of specialized diabetes care; edit. by Dedov I.I., Shestakov M.V., Mayorov A.Y., 8th edit. Moscow: UP PRINT; 2017:112 (In Russ.).Palmieri V., Bella J.N., Arnett D.K., Liu J.E., Oberman A., Schuck M.Y. et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) Study. Circulation. 2001;103(1):102–107. DOI: 10.1161/01.cir.103.1.102.Palmieri V., Bella J.N., Arnett D.K., Liu J.E., Oberman A., Schuck M.Y. et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) Study. Circulation. 2001;103(1):102–107. DOI: 10.1161/01.cir.103.1.102.Fox C.S. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc. Med. 2010;20(3):90–95. DOI: 10.1016/j.tcm.2010.08.001.Fox C.S. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc. Med. 2010;20(3):90–95. DOI: 10.1016/j.tcm.2010.08.001.Королева Е.В., Хохлов А.Л. Факторы, влияющие на развитие структурно-функциональных нарушений сердца у больных сахарным диабетом 2-го типа. Международный научно-исследовательский журнал. 2017;58(4):156–159. DOI: 10.23670/IRJ.2017.58.152.Koroleva E.V., Khokhlov A.L. Factors affecting the development of structural and functional heart disorders in patients with type 2 diabetes. International Research Journal. 2017;58(4):156–159 (In Russ.). DOI: 10.23670/IRJ.2017.58.152.19.Sprenkeler D.J., Vos M.A. Post-extrasystolic potentiation: Link between Ca(2+) homeostasis and heart failure? Arrhythm. Electrophysiol. Rev. 2016;5(1):20–26. DOI: 10.15420/aer.2015.29.2.Sprenkeler D.J., Vos M.A. Post-extrasystolic potentiation: Link between Ca(2+) homeostasis and heart failure? Arrhythm. Electrophysiol. Rev. 2016;5(1):20–26. DOI: 10.15420/aer.2015.29.2.Zima A.V., Kockskȁmper J., Blatter L.A. Cytosolic energy reserves determine the effect of glycolytic sugar phosphates on sarcoplasmic reticulum Ca2+ release in cat ventricular myocytes. J. Physiol. 2006;577(1):281–293. DOI: 10.1113/jphysiol.2006.117242.Zima A.V., Kockskȁmper J., Blatter L.A. Cytosolic energy reserves determine the effect of glycolytic sugar phosphates on sarcoplasmic reticulum Ca2+ release in cat ventricular myocytes. J. Physiol. 2006;577(1):281–293. DOI: 10.1113/jphysiol.2006.117242.Ritterhoff J., Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc. Res. 2017;113(4):411–421. DOI: 10.1093/cvr/cvx017.Ritterhoff J., Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc. Res. 2017;113(4):411–421. DOI: 10.1093/cvr/cvx017

The authors declare that there are no conflicts of interest present.